|Articles|May 1, 2001

Artherosclerosis: Achieving Optimal Outcomes in Statin Therapy
Volume 7
Issue 5 Suppl

What Do the Statin Trials Tell Us?

Author(s)David D. Waters, MD

Download PDF: What Do the Statin Trials Tell Us?

Articles in this issue

over 25 years ago

Article

Participating Faculty

over 25 years ago

Article

Introduction

over 25 years ago

Article

Should All Patients with Cardiovascular Disease Receive Statin Therapy?

over 25 years ago

Article

Threshold Level or Not for Low-Density Lipoprotein Cholesterol

over 25 years ago

Article

Statins--Differences and Similarities

over 25 years ago

Article

Surrogate Endpoints and Newer Risk Markers in Atherosclerosis Management

over 25 years ago

Article

New Therapies on the Horizon

over 25 years ago

Article

A New Statin: A New Standard

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

What Do the Statin Trials Tell Us?

Articles in this issue

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Trending on AJMC

FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer

FDA Panel Backs 6 Peptides for Compounding

Atacicept Becomes First BAFF/APRIL Inhibitor Approved for IgA Nephropathy: Richard Lafayette, MD

Boston Panel Confronts Access and Coordination Gaps in Obesity Care

Pediatric Chronic Skin Disorders Linked to Poorer Mental Health

A Look at PBM Reform and Transparency: Payer, Provider and Patient Impact

What Do the Statin Trials Tell Us?

Articles in this issue

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Trending on AJMC

FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer

FDA Panel Backs 6 Peptides for Compounding

Atacicept Becomes First BAFF/APRIL Inhibitor Approved for IgA Nephropathy: Richard Lafayette, MD

Boston Panel Confronts Access and Coordination Gaps in Obesity Care

Pediatric Chronic Skin Disorders Linked to Poorer Mental Health